Document Detail


Effects of a perindopril-based blood pressure lowering regimen on cardiac outcomes among patients with cerebrovascular disease.
MedLine Citation:
PMID:  12633548     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
AIM: To determine the effects of a perindopril-based blood pressure lowering regimen on major cardiac events among hypertensive and non-hypertensive patients with a history of cerebrovascular disease. METHODS AND RESULTS: A total of 6105 individuals with a history of stroke or transient ischaemic attack were randomly assigned active treatment (n=3051) or placebo (n=3054). Active treatment comprised the angiotensin-converting-enzyme inhibitor perindopril (4 mg daily), with the addition of the diuretic indapamide at the discretion of treating physicians. Over a mean of 3.9 years of follow-up, active treatment reduced blood pressure by 9/4 mm Hg compared with placebo and reduced the primary outcome, stroke, by 28%. Major coronary events occurred in 269 participants (active 3.8%, placebo 5.0%) and heart failure was diagnosed in 264 participants (active 3.7%, placebo 4.9%). Active treatment reduced the risk of major coronary events by 26% (95% CI: 6-42%; p=0.02) and the risk of congestive heart failure by 26% (5-42%; p=0.02). For each of these outcomes, there was no clear evidence of differences between the treatment effects in participants classified as hypertensive or non-hypertensive, and those with or without a history of coronary heart disease. CONCLUSIONS: Among individuals with cerebrovascular disease, blood pressure lowering with a regimen involving perindopril and indapamide not only reduced the risk of stroke, but also substantially reduced the risks of cardiac outcomes.
Authors:
Related Documents :
20706198 - Age-dependent association between sleep duration and hypertension in the adult korean p...
1347678 - Level of blood pressure and risk of myocardial infarction among treated hypertensive pa...
2045178 - Predictors of an increased risk of future hypertension in utah. a screening analysis.
8688758 - Cardiovascular risk factors in british children from towns with widely differing adult ...
7255868 - Bioenergetics in clinical medicine. xvi. reduction of hypertension in patients by thera...
20584068 - Myocardial strain characterization in different left ventricular adaptative responses t...
Publication Detail:
Type:  Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  European heart journal     Volume:  24     ISSN:  0195-668X     ISO Abbreviation:  Eur. Heart J.     Publication Date:  2003 Mar 
Date Detail:
Created Date:  2003-03-13     Completed Date:  2003-05-05     Revised Date:  2009-11-03    
Medline Journal Info:
Nlm Unique ID:  8006263     Medline TA:  Eur Heart J     Country:  England    
Other Details:
Languages:  eng     Pagination:  475-84     Citation Subset:  IM    
Affiliation:
PROGRESS Collaborative Group c/o Institute for International Health, University of Sydney, PO Box 576, Newtown, NSW 2042, Sydney, Australia.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Angiotensin-Converting Enzyme Inhibitors / therapeutic use*
Antihypertensive Agents / therapeutic use*
Cerebrovascular Disorders / complications,  drug therapy*
Coronary Disease / prevention & control*
Death, Sudden, Cardiac
Female
Heart Failure / prevention & control
Humans
Hypertension / prevention & control*
Male
Middle Aged
Perindopril / therapeutic use*
Risk Factors
Treatment Outcome
Chemical
Reg. No./Substance:
0/Angiotensin-Converting Enzyme Inhibitors; 0/Antihypertensive Agents; 82834-16-0/Perindopril
Comments/Corrections
Comment In:
Eur Heart J. 2003 Mar;24(5):391-3   [PMID:  12633540 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  The EuroHeart Failure Survey programme--a survey on the quality of care among patients with heart fa...
Next Document:  APC, beta-Catenin and hTCF-4; an unholy trinity in the genesis of colorectal cancer.